Enliven Therapeutics Inc (ELVN)

$38.99 +2.40 (6.56%)
Market Cap 2.32B
Revenue (ttm) 0.00
Net Income (ttm) -103.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,127,655
Avg Vol 1,114,278
Day's Range N/A - N/A
Shares Out 59.80M
Stochastic %K 71%
Beta 0.33
Analysts Strong Sell
Price Target $43.88

Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatm...

Industry: Biotechnology
Sector: Healthcare
Phone: 720 647 8519
Address:
6200 Lookout Road, Boulder, United States
Spicy_Trade
Spicy_Trade Mar. 28 at 6:56 PM
SpicyTrade Enliven Therapeutics, Inc. ( $ELVN ) daily stock analysis https://youtu.be/afDwMeMmMmQ?si=4x-PLja7Ym4GVUf0
0 · Reply
WycklyTrader
WycklyTrader Mar. 26 at 7:55 PM
Friday momo watch: $KOD $KALV $RLAY $ELVN $PGEN $ PLYX...
0 · Reply
Few_erish
Few_erish Mar. 26 at 6:42 PM
$ELVN that candle though
0 · Reply
naz2hi
naz2hi Mar. 26 at 5:45 PM
$ELVN $KOD ... might be safer to sit out this Trumpenstein zio-warmongering feuled mkt collapse w/ these winners. Now🙏 the 🍊 f*cktard doesn't actually go thru w/ his asinine plan of trying to invade Iran w/ marines. Which will probably lead in them getting killed and oil 🛢️ shooting up instantaneous to over $150, or possibly higher. As well as ushering in a worldwide economy disaster not seen in almost 100 yrs.
0 · Reply
thedentite
thedentite Mar. 26 at 2:13 PM
$ELVN Perhaps the best stock purchase I've made
0 · Reply
DonCorleone77
DonCorleone77 Mar. 26 at 10:25 AM
$ELVN Enliven price target raised to $56 from $48 at H.C. Wainwright H.C. Wainwright raised the firm's price target on Enliven (ELVN) to $56 from $48 and keeps a Buy rating on the shares. The firm believes Merck's (MRK) acquisition of Terns Pharmaceuticals (TERN) poses a threat to other major pharma companies. Novartis (NVS) could be the most likely pharma company to express interest in acquiring Enliven given the strategic need, the analyst tells investors in a research note. "From our perspective, the Terns acquisition does not detract from Enliven's value proposition; in fact, quite the opposite," contends H.C. Wainwright.
0 · Reply
NeonHornet
NeonHornet Mar. 25 at 8:54 PM
~|~@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of traders on this platform. ~|~If you’re not following yet, you’re missing out. It takes 2 seconds and it’s completely free. 💎 $ELVN $ZGM $WTF $TWAV *2:
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 25 at 7:54 PM
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio $ELVN $TERN $MRK https://stocktwits.com/news/equity/markets/terns-buyout-deal-ignites-optimism-for-enliven-therapeutics-blood-cancer-portfolio/cZ3Y6W6RIjP
0 · Reply
notreload_ai
notreload_ai Mar. 25 at 7:49 PM
$MRK $6.7B acquisition of $TERN highlights huge potential in CML therapies. Why analysts see $ELVN ELVN-001 as a best-in-class winner with strong takeover appeal. https://notreload.xyz/merck-terns-deal-boosts-enliven-therapeutics/
0 · Reply
erevnon
erevnon Mar. 25 at 6:13 PM
Mizuho maintains Enliven Therapeutics $ELVN at Outperform and raises the price target from $41 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Latest News on ELVN
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:05 PM EST - 4 weeks ago

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

Jan 8, 2026, 2:16 PM EST - 2 months ago

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Jan 8, 2026, 9:00 AM EST - 2 months ago

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Jan 7, 2026, 9:00 AM EST - 2 months ago

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Dec 11, 2025, 4:21 PM EST - 3 months ago

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Dec 11, 2025, 9:00 AM EST - 3 months ago

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy

Nov 18, 2025, 7:55 AM EST - 4 months ago

Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Nov 12, 2025, 4:05 PM EST - 4 months ago

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Aug 25, 2025, 6:20 PM EDT - 7 months ago

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Aug 13, 2025, 4:05 PM EDT - 8 months ago

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 16, 2025, 4:05 PM EDT - 10 months ago

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 9:30 AM EDT - 10 months ago

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 6:10 AM EDT - 10 months ago

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Jun 13, 2025, 6:02 AM EDT - 10 months ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Enliven Therapeutics to Present at Upcoming Investor Conferences

May 22, 2025, 4:05 PM EDT - 11 months ago

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

May 14, 2025, 4:05 PM EDT - 11 months ago

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

May 14, 2025, 9:56 AM EDT - 11 months ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Apr 2, 2025, 4:03 PM EDT - 1 year ago

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Final Trade: CVX, XLE, ELVN, COF

Mar 21, 2025, 6:38 PM EDT - 1 year ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH IBB

Enliven's Early Data Stands Out From Peers

Jan 7, 2025, 12:28 AM EST - 1 year ago

Enliven's Early Data Stands Out From Peers

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Why Enliven is this analyst's top biotech stock pick

Oct 18, 2024, 7:18 PM EDT - 1 year ago

Why Enliven is this analyst's top biotech stock pick

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Sep 28, 2024, 9:35 AM EDT - 1 year ago

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

May 29, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Apr 11, 2024, 7:55 AM EDT - 2 years ago

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Apr 9, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Mar 19, 2024, 8:30 AM EDT - 2 years ago

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 14, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Feb 27, 2024, 4:05 PM EST - 2 years ago

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Enliven Therapeutics: Preclinical Company With Interesting Value Proposition

Aug 18, 2023, 12:57 PM EDT - 2 years ago

Enliven Therapeutics: Preclinical Company With Interesting Value Proposition

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Feb 23, 2023, 5:20 PM EST - 3 years ago

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Imara Announces Stockholder Approval of Merger With Enliven

Feb 22, 2023, 4:01 PM EST - 3 years ago

Imara Announces Stockholder Approval of Merger With Enliven

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Jan 25, 2023, 1:07 PM EST - 3 years ago

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Enliven Therapeutics and Imara Announce Merger Agreement

Oct 13, 2022, 4:35 PM EDT - 3 years ago

Enliven Therapeutics and Imara Announce Merger Agreement

Imara: Potential Liquidation

Sep 29, 2022, 3:06 PM EDT - 3 years ago

Imara: Potential Liquidation

Read Why Imara Shares Are Falling Today

Apr 5, 2022, 10:13 AM EDT - 4 years ago

Read Why Imara Shares Are Falling Today

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Apr 5, 2022, 6:45 AM EDT - 4 years ago

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

Mar 15, 2022, 11:06 AM EDT - 4 years ago

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Mar 8, 2022, 7:00 AM EST - 4 years ago

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Feb 10, 2022, 7:00 AM EST - 4 years ago

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Imara To Start Testing Tovinontrine In Heart Failure Patients

Jan 25, 2022, 11:03 AM EST - 4 years ago

Imara To Start Testing Tovinontrine In Heart Failure Patients

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Jan 25, 2022, 7:00 AM EST - 4 years ago

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Spicy_Trade
Spicy_Trade Mar. 28 at 6:56 PM
SpicyTrade Enliven Therapeutics, Inc. ( $ELVN ) daily stock analysis https://youtu.be/afDwMeMmMmQ?si=4x-PLja7Ym4GVUf0
0 · Reply
WycklyTrader
WycklyTrader Mar. 26 at 7:55 PM
Friday momo watch: $KOD $KALV $RLAY $ELVN $PGEN $ PLYX...
0 · Reply
Few_erish
Few_erish Mar. 26 at 6:42 PM
$ELVN that candle though
0 · Reply
naz2hi
naz2hi Mar. 26 at 5:45 PM
$ELVN $KOD ... might be safer to sit out this Trumpenstein zio-warmongering feuled mkt collapse w/ these winners. Now🙏 the 🍊 f*cktard doesn't actually go thru w/ his asinine plan of trying to invade Iran w/ marines. Which will probably lead in them getting killed and oil 🛢️ shooting up instantaneous to over $150, or possibly higher. As well as ushering in a worldwide economy disaster not seen in almost 100 yrs.
0 · Reply
thedentite
thedentite Mar. 26 at 2:13 PM
$ELVN Perhaps the best stock purchase I've made
0 · Reply
DonCorleone77
DonCorleone77 Mar. 26 at 10:25 AM
$ELVN Enliven price target raised to $56 from $48 at H.C. Wainwright H.C. Wainwright raised the firm's price target on Enliven (ELVN) to $56 from $48 and keeps a Buy rating on the shares. The firm believes Merck's (MRK) acquisition of Terns Pharmaceuticals (TERN) poses a threat to other major pharma companies. Novartis (NVS) could be the most likely pharma company to express interest in acquiring Enliven given the strategic need, the analyst tells investors in a research note. "From our perspective, the Terns acquisition does not detract from Enliven's value proposition; in fact, quite the opposite," contends H.C. Wainwright.
0 · Reply
NeonHornet
NeonHornet Mar. 25 at 8:54 PM
~|~@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of traders on this platform. ~|~If you’re not following yet, you’re missing out. It takes 2 seconds and it’s completely free. 💎 $ELVN $ZGM $WTF $TWAV *2:
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 25 at 7:54 PM
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio $ELVN $TERN $MRK https://stocktwits.com/news/equity/markets/terns-buyout-deal-ignites-optimism-for-enliven-therapeutics-blood-cancer-portfolio/cZ3Y6W6RIjP
0 · Reply
notreload_ai
notreload_ai Mar. 25 at 7:49 PM
$MRK $6.7B acquisition of $TERN highlights huge potential in CML therapies. Why analysts see $ELVN ELVN-001 as a best-in-class winner with strong takeover appeal. https://notreload.xyz/merck-terns-deal-boosts-enliven-therapeutics/
0 · Reply
erevnon
erevnon Mar. 25 at 6:13 PM
Mizuho maintains Enliven Therapeutics $ELVN at Outperform and raises the price target from $41 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Few_erish
Few_erish Mar. 25 at 4:30 PM
$ELVN another push maybe
0 · Reply
Quantumup
Quantumup Mar. 25 at 2:46 PM
Clear Street reiterated $ELVN Buy; $36 $MRK - $TERN $NVS Here's what Clear Street said in its note to investors: https://x.com/Quantumup1/status/2036816061606096961?s=20
1 · Reply
thedentite
thedentite Mar. 25 at 2:33 PM
$ELVN Why didn't I put every penny I own into this? Bah! Come on, $ALT be more like Enliven. Also I should really stop putting every penny I own into a single thing. But hey, if you want to punch someone in the nose aim for the back of the head.
0 · Reply
StockElementCorporation
StockElementCorporation Mar. 25 at 1:14 PM
Premarket movers 📈 Upside: $DXYZ +30% — SpaceX IPO speculation $BRZE +20% — momentum $ELVN +18% — sympathy to Merck/Terns deal $QNRX +16% — FDA supports single Phase 3 path $ARM +12% — investor day guidance DNLI +11% — FDA BLA approval NOTE +11% — OpenAI app launch CHWY +7.9% — earnings TERN +5.6% — $53 Merck buyout PDD +4.5% — earnings ONDS +4.4% — earnings BEAM +4.2% — positive clinical data JD +3.8% — China policy support HOOD +3.5% — $1.5B buyback BABA +3.4% — China policy support SRPT +3.4% — early trial data PAYX +3.3% — earnings Downside: AVXL -31% — EU Alzheimer’s application withdrawn
0 · Reply
topstockalerts
topstockalerts Mar. 25 at 11:58 AM
Pre Market Top Gainers $ITOC $BZAI $ARMG $NXTT $ELVN
1 · Reply
TheTinyDevil
TheTinyDevil Mar. 25 at 9:55 AM
$ELVN Anyone have any insight on the jump here in premarket? Really not at all familiar w/the ticker... I see no news/PR, no other posts on here (though I haven't checked any filings). Bid is over $36 on 5700 shares, so it's not a fluke.
1 · Reply
SuperGreenToday
SuperGreenToday Mar. 25 at 12:16 AM
$ELVN Share Price: $31.15 Contract Selected: Dec 18, 2026 $30 Calls Buy Zone: $5.52 – $6.83 Target Zone: $9.45 – $11.54 Potential Upside: 61% ROI Time to Expiration: 268 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
PaulLaurent
PaulLaurent Mar. 23 at 7:36 AM
🧨 Short Squeeze Candidates — Week of March 23, 2026 $ELVN – short score 68,43/100 – News (72h): no confirmed fresh PR; the latest visible company update remains its March 3 Q4 and full-year 2025 business update. $EZPW – short score 81,20/100 – News (72h): no confirmed fresh PR; the recent company backdrop still centers on strong Q1 fiscal 2026 results, higher pawn loans, and acquisition-driven expansion. $RXT – short score 74,30/100 – News (72h): Rackspace and Rubrik launched a UK Sovereign Cyber Recovery Cloud, giving the name a fresh enterprise security and sovereign-cloud headline. $CURV – short score 80,44/100 – News (72h): Torrid reported Q4 and fiscal 2025 results and initiated fiscal 2026 guidance, putting the turnaround and forward outlook back in focus. $RCAT – short score 67,77/100 – News (72h): Red Cat reported record Q4 revenue growth, 161% full-year revenue growth, and highlighted expanded production capacity heading into 2026.
0 · Reply
topstockalerts
topstockalerts Mar. 19 at 7:06 PM
$ELVN thinner and reactive, can spike hard on not much volume. Needs confirmation before chasing.
0 · Reply
AC_TRADER
AC_TRADER Mar. 19 at 6:24 PM
$ELVN trying to go... chart: https://share.trendspider.com/chart/ELVN/7594xstl26
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 12:52 PM
$ELVN RSI: 41.12, MACD: 0.5296 Vol: 1.39, MA20: 28.62, MA50: 26.73 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
GRASSFEDBEEF
GRASSFEDBEEF Mar. 5 at 2:20 PM
$ELVN The Enliven Therapeutics, Inc. stock price gained 4.28% on the last trading day (Wednesday, 4th Mar 2026), rising from $28.75 to $29.98. During the last trading day the stock fluctuated 9.01% from a day low at $27.97 to a day high of $30.49. The price has risen in 6 of the last 10 days and is up by 13.69% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 237 thousand more shares were traded than the day before. In total, 895 thousand shares were bought and sold for approximately $26.82 million. The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 66.11% during the next 3 months and, with a 90% probability hold a price between $40.98 and $60.18 at the end of this 3-month period.
0 · Reply